Penumbra, Inc.
Alış

Penumbra: Richly-valued but trades well after earnings

88
Nov 5th, 3:12 pm
PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M

Nov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for JNJ MDT or even EW

Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.

PEN

Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.